¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022³â Á¦14ȸ ´ëÇÑÅðÇ༺½Å°æÁúȯÇÐȸ Çмú´ëȸ : 2022-09-24

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022³â Á¦14ȸ ´ëÇÑÅðÇ༺½Å°æÁúȯÇÐȸ Çмú´ëȸ : 2022-09-24
±³À°ÀÏÀÚ : 2022-09-24
±³À°Àå¼Ò : ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ  
±³À°ÁÖÁ¦ : 2022³â Á¦14ȸ ´ëÇÑÅðÇ༺½Å°æÁúȯÇÐȸ Çмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѽŰæ°úÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÅðÇ༺½Å°æÁúȯÇÐȸ  
´ã´çÀÚ : À̹̼±
¿¬¶ôó : 02-440-7240  
À̸ÞÀÏ : office.ksnd@gmail.com      
±³À°Á¾·ù : ½Å°æ°ú      
Âü¼®¿¹»óÀοø : 250¸í 
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 55ºÐ  
¼¼ºÎ¼ö°­·á : 100,000¿ø      
ºñ°í »çÀüµî·Ï(ÁØȸ¿ø 3¸¸¿ø, Á¤È¸¿ø/ÀÌ»çÁø 5¸¸¿ø), ´çÀϵî·Ï(ÁØȸ¿ø 5¸¸¿ø, Á¤È¸¿ø/ÀÌ»çÁø 7¸¸¿ø), ºñȸ¿ø(ÁØȸ¿ø±Þ 8¸¸¿ø, Á¤È¸¿ø±Þ 10¸¸¿ø)      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:00~09:30 Registration  () 
±âŸ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:30~09:40 Opening Remark  ÃÖº´¿Á(¼º±Õ°ü´ë) 
±³À°½Ã°£ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:40~09:55 Alzheimer disease  ¹Ú¿µÈ£(ºÐ´ç¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 09:55~10:10 Parkinson¡¯s disease  ½Åä¿ø(Ãæ³²´ë) 
±³À°½Ã°£ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:10~10:25 Motor neuron disease  ÃÖ¼®Áø(¼­¿ï´ë) 
±³À°½Ã°£ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:25~10:40 Peripheral nerve disease  À±º°¾Æ(µ¿¾Æ´ë) 
È޽Ġ09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 10:40~11:00 Break  () 
±³À°½Ã°£ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 11:00~11:40 Impaired dynamics of phase transition and neuro-inflammation in neurodegenerative diseases  ±è½ÂÇö(ÇѾç´ë) 
±³À°½Ã°£ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 11:40~12:20 Proteostasis and Pathogenic Mechanism of Alzheimer¡¯s Disease  Á¤¿ë±Ù(¼­¿ï´ë) 
½Ä»ç 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 12:20~13:20 ÃÑȸ ¹× Lunch  () 
±³À°½Ã°£ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ A 13:25~13:50 The CDK4/6 inhibitor abemaciclib mesylate regulates A¥â/tau pathology, neuroinflammation and Ab/LPS-mediated cognitive impairment  ÇãÇâ¼÷(Çѱ¹³ú¿¬±¸¿ø) 
±³À°½Ã°£ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ A 13:50~14:15 The Critical Role of Nurr1 as a Mediator and Therapeutic Target in Alzheimer's Disease-related Pathogenesis  ¹®¹ÎÈ£(°Ç¾çÀÇ´ë) 
±³À°½Ã°£ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ A 14:15~14:40 Alteration of intestinal immune cells in the APP/PS1 mice with DSS-induced colitis  ¾ç½ÂÈÆ(µ¿±¹´ë) 
±³À°½Ã°£ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ B 13:20~14:40 How to develop and manage biotech companies  TBA() 
±âŸ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 14:40~15:20 Guided Poster session  ÇмúÀ§¿ø() 
±³À°½Ã°£ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ A 15:20~15:40 High-sensitivity immunoassay of beta-amyloid contained in plasma extracellular vesicles in Alzheimer's disease patients 3  °­ÁöÀ±(KIST) 
±³À°½Ã°£ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ A 15:40~16:00 Blood biomarkers in AD: current and future landscape  °í¼ºÈ£(ÇѾç´ë) 
±³À°½Ã°£ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ A 16:00~16:20 Neuroimaging markers in neurodegeneration  Á¤¿ë(KAIST) 
±³À°½Ã°£ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ B 15:20~15:40 Peripheral nerve disease modeling  ±è¿ëÁØ(°æÈñ´ë) 
±³À°½Ã°£ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ B 15:40~16:00 Mouse models for Amyotrophic Lateral Sclerosis  È«¿µºó(µ¿¾Æ´ëÇб³) 
±³À°½Ã°£ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ B 16:00~16:20 Modeling Alzheimer's disease using human iPSC-derived brain organoids  ¼­Áø¼ö(DGIST) 
È޽Ġ09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 16:20~16:30 Break  () 
±âŸ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 16:30~17:20 Oral presentation session  À̽ÂÀç(¼­¿ïÀÇ´ë) 
±âŸ 09-24 ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ 17:20~17:30 Award & Closing  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022³â Á¦14ȸ ´ëÇÑÅðÇ༺½Å°æÁúȯÇÐȸ Çмú´ëȸ : 2022-09-24""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 2022³âµµ Çѱ¹Á¤½ÅºÐ¼®ÇÐȸ Á¤½ÅÄ¡·á Àü¹®°úÁ¤: Á¤½ÅºÐ¼®Àû Ä¡·áÀÇ ÁÖ¿ä °³³äµé°ú ÀÓ»óÀû È°¿ë 1 : 2022-09-24
´ÙÀ½±Û 2022 Á¦ 23ȸ ´ëÇѽŰæÁßȯÀÚÀÇÇÐȸ ¿¬¼ö°­Á : 2022-09-24
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21062 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(4ÀÏÂ÷) : 2024-07-04 0 119 2024-06-18
21061 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ÀçÅÃÀÇ·á ȯÀÚ Áø·áÀÇ ½ÇÁ¦ : 2024-07-04 0 70 2024-06-18
21060 ¿ï»ê ´ëÇÑ»êºÎÀΰúÀÇ»çȸ ¿ï»êÁöȸ ¿¬¼ö±³À°(¿ù°æÅë, µ¥³ë¼ö¹ä Áß´Ü ÈÄ ¹Ýµ¿°ñÀýÀÇ ¿¹¹æ) : 2024-07-04 0 98 2024-06-18
21059 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(3ÀÏÂ÷) : 2024-07-03 0 19 2024-06-18
21058 °æ±â 2024³â ÆòÅýÃÀÇ»çȸ ÇÏ°èÇмú´ëȸ : 2024-07-02 0 109 2024-06-18
21057 ¼­¿ï ¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(2ÀÏÂ÷) : 2024-07-02 0 83 2024-06-18
21056 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 64 2024-06-18
21055 ¼­¿ï (¿Â¶óÀÎ)¹ÙÀÌ¿Àºòµ¥ÀÌÅÍÀÇ È°¿ë°ú ÃֽŠ¿ªÇÐ ¼³°è ¹× ±â°èÇнÀ(1ÀÏÂ÷) : 2024-07-01 0 63 2024-06-18
21054 ÃæºÏ ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ Understanding Current Community Mental Health and Emotional Disorders in ASD : 2024-07-01 0 93 2024-06-18
21053 ¼­¿ï (¿Â¶óÀÎ) 2024³âµµ °³¿øÀÇ ½ÉÆ÷Áö¾ö : 2024-06-30 0 59 2024-06-18
21052 °æ±â ´ëÇÑÁ¤ÇüÅëÁõÀÇÇÐȸ - Á¦2ȸ CHAMS °³¿øÀÇ ½ÉÆ÷Áö¾ö : 2024-06-30 0 63 2024-06-18
21051 ¼­¿ï 2024³â ´ëÇÑ°¡Á¤ÀÇÇÐȸ ¼­¿ïÁöȸ Çϰ迬¼ö°­Á : 2024-06-30 0 78 2024-06-18
21050 ºÎ»ê 2024³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ ¿¬¼ö°­Á : 2024-06-30 0 35 2024-06-18
21049 ¼­¿ï Á¦26Â÷ ´ëÇѾƵ¿º´¿øÇùȸ Ãá°èÇмú´ëȸ : 2024-06-30 0 26 2024-06-18
21048 Ãæ³² 2024 ÀÌ°úÇÐ ¿¬±¸¼¼¹Ì³ª : 2024-06-29 0 27 2024-06-18
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷